Chemomab Therapeutics Ltd. Sponsored ADR

CMMB Healthcare Biotechnology

EPS
+25.0%
Free cash flow
+47.9%

Quarter to June 2026, against a year earlier

1.28 0.03 +2.40%
Market cap
$9.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

10.49 9.08 10.31 6.41
Net Debt/EBITDA
5.53 5.25 4.35 2.98
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 (1.42) 0.00 (0.47)
Book value per Share
0.45 1.58 1.34 1.09
Free Cash Flow
— (11.13) — (3.75)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026